Skip to main content
. 2019 Nov 11;25:e20190038. doi: 10.1590/1678-9199-JVATITD-2019-0038

Figure 3. The heterologous fibrin sealant (HFS) produced by CEVAP. (A) Fractions, (B) stable clot formed after mixture of the components.

Figure 3.